Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study
PROTEOMICS – Clinical Applications · 2025
DOI: 10.1002/prca.70021 ↗At a glance
Journal article in PROTEOMICS – Clinical Applications, 2025. Written by Oraianthi Fiste and 8 co-authors. Institution: Department of Clinical Therapeutics & Laboratory, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. Major MEDLINE topics: Aminopyridines, Purines, Cardiovascular Diseases. 69 references.
Abstract (original language)
Cyclin‐dependent kinase 4/6 inhibitors have transformed hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative metastatic breast cancer (BC) therapeutics. Ribociclib has been associated with survival gain, yet its potential cardiovascular toxicities (CVTs) remain an area of uncertainty. Our single‐center study prospectively recruited adult patients in order to assess treatment‐related CVT incidence and spectrum as well as decipher proteins’ differential expression in affected patients by data‐independent acquisition liquid chromatography‐tandem mass spectrometry (DIA LC‐MS/MS). After a median follow‐up of 27.2 months, five cases of CVT have occurred among the 62 enrolled participants (8.06%; mean age, 67 years). CVTs were in the form of asymptomatic QTc prolongation, transient ischemic attack, deep vein thrombosis, syncope, and pericardial effusion, which developed within 7.56 months. The in‐depth proteomics quantified 144 differentially expressed proteins, of which 109 and 35 were down‐ and up‐regulated, respectively, in these five cases (enrolled participants with CVT) compared to five sex‐ and age‐matched controls (enrolled participants without CVT). Negative regulation of endopeptidase activity, phosphatidylcholine metabolism, and immune response were the most affected signaling pathways in the subsequent functional analysis. Large‐scale external validation of our hypothesis‐generating findings could potentially support individualized cardiovascular prevention in BC patients under ribociclib combinational therapy. Summary Ribociclib has unequivocally revolutionized hormone‐dependent metastatic breast cancer therapeutics. Its potential cardiotoxicity, however, remain inadequately characterized, whereas the underlying pathophysiological mechanisms are poorly understood so far. Our prospective case–control study revealed that despite cardiovascular toxicity was not very common (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Therapeutics & Laboratory, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
- Institute For Bioinnovation, Biomedical Sciences Research Center "Alexandrer Fleming", Vari, Greece.
- First Department of Obstetrics and Gynecology, Alexandra University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
ORCID profiles: Oraianthi Fiste
Cite
APA
Fiste, O., Samiotaki, M., Manios, E., Trika, C., Liacos, C. I., Dimitrakakis, C., Dimopoulos, M. A., Gavriatopoulou, M., & Zagouri, F. (2025). Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.70021
Vancouver
Fiste O, Samiotaki M, Manios E, Trika C, Liacos CI, Dimitrakakis C, et al. Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study. PROTEOMICS – Clinical Applications. 2025. doi:10.1002/prca.70021
BibTeX
@article{Fiste2025,
author = {Fiste, Oraianthi and Samiotaki, Martina and Manios, Efstathios and Trika, Chrysanthi and Liacos, Christine Ivy and Dimitrakakis, Constantine and Dimopoulos, Meletios Athanasios and Gavriatopoulou, Maria and Zagouri, Flora},
title = {Serum Proteomics of Ribociclib‐Mediated Cardiovascular Toxicity: An Exploratory Case–Control Study},
journal = {PROTEOMICS – Clinical Applications},
year = {2025},
doi = {10.1002/prca.70021}
}
EUVIMED